What Researchers Did
Researchers investigated whether volatile organic compounds (VOCs) could be detected in exhaled breath as markers of pulmonary oxygen toxicity after hyperbaric oxygen therapy (HBOT) in ten healthy volunteers.
What They Found
After gas chromatography-mass spectrometry (GC-MS) analysis, eleven relevant volatile organic compounds (VOCs) were identified from exhaled breath samples, which were clustered into two principal components (PC). Principal Component 1, comprising inflammation-associated VOCs, showed no significant change over the study period.
What This Means for Canadian Patients
If validated, these findings could lead to new, non-invasive methods for Canadian patients undergoing hyperbaric oxygen therapy to monitor for early signs of pulmonary oxygen toxicity. This might allow for more personalized treatment adjustments, potentially reducing side effects like fatigue and pulmonary complaints.
Canadian Relevance
This study has no direct Canadian connection as it was conducted in the Netherlands with Royal Netherlands Navy volunteers.
Study Limitations
A key limitation is the small sample size of ten healthy volunteers, which may not fully represent the broader patient population receiving hyperbaric oxygen therapy.